Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

5.39
+0.07001.32%
Post-market: 5.440.0500+0.93%19:13 EDT
Volume:1.99M
Turnover:10.61M
Market Cap:970.67M
PE:-12.78
High:5.40
Open:5.27
Low:5.19
Close:5.32
52wk High:6.88
52wk Low:1.33
Shares:180.09M
Float Shares:119.00M
Volume Ratio:1.24
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4216
EPS(LYR):-0.4216
ROE:-41.29%
ROA:-25.29%
PB:4.93
PE(LYR):-12.78

Loading ...

Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler

TIPRANKS
·
Nov 10, 2025

Compass Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position

TIPRANKS
·
Nov 06, 2025

Compass Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 05, 2025

Compass Therapeutics Q3 EPS $(0.08) Beats $(0.14) Estimate

Benzinga
·
Nov 05, 2025

Compass Therapeutics posts $14.3 million net loss for third quarter 2025

Reuters
·
Nov 05, 2025

Compass Therapeutics Inc. - Expects Phase 2/3 Companion-002 Study of Tovecimig Os and Pfs Data in Late Q1 2026

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Q3 EPS USD -0.08

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Q3 Net Income USD -14.259 Million

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Inc. - Plans Ctx-10726 Ind Filing for Q4 2025 With Initial Phase 1 Clinical Data Expected in H2 2026

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Nov 05, 2025

Compass Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Oct 22, 2025

Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment

TIPRANKS
·
Oct 13, 2025

Compass Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
Oct 06, 2025

Compass Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Oct 02, 2025